TREML2 (TREM-like transcript 2) is a member of the triggering receptor expressed on myeloid cells (TREM) family of proteins. It is a single-pass type I membrane protein with an Ig-like V-type domain that plays important roles in immune cell function, particularly in myeloid cells including microglia, macrophages, and dendritic cells [1][2]. TREML2 has emerged as a significant protein in neurodegenerative disease research due to its genetic association with Alzheimer's disease risk and its role in microglial phagocytosis and neuroinflammation [3][4].
The TREM family includes several related proteins: TREM1, TREM2, TREML1, TREML2, TREML3, and TREML4. While TREM2 has received extensive attention in AD research following the discovery of disease-associated variants, TREML2 shares structural similarity and has complementary or distinct functions in immune regulation [5][6]. TREML2 is expressed primarily in myeloid cells and is particularly important in the central nervous system where it modulates microglial function.
¶ Structure and Biochemistry
TREML2 is a type I transmembrane protein with the following structural features [7][8]:
- Extracellular Ig-like domain: The N-terminal portion contains an immunoglobulin V-type (IgV) domain that mediates ligand binding. This domain shares approximately 40% sequence similarity with TREM2's IgV domain.
- Transmembrane domain: A short hydrophobic transmembrane helix anchors the protein in the cell membrane
- Cytoplasmic tail: Contains a short cytoplasmic domain with potential signaling motifs
TREML2 shares significant structural and functional homology with TREM2:
- Both proteins have similar Ig-like extracellular domains
- Both signal through the same adaptor protein DAP12 (TYROBP)
- However, TREML2 has distinct ligand specificity and expression patterns
- TREML2 may act as a functional paralog or decoy receptor for TREM2 ligands
¶ Ligand Interactions
TREML2 binds to various ligands including [9][10]:
- Lipids: Various lipid species including phosphatidylserine and oxidized lipids
- Apolipoproteins: ApoE and other apolipoproteins
- Bacterial products: Certain bacterial cell wall components
- TREM2 ligands: May compete with or complement TREM2 ligand binding
TREML2 plays multiple roles in immune cell function [11][12]:
- TREML2 regulates cytokine production by macrophages and dendritic cells
- Can both enhance and suppress inflammatory responses depending on context
- Modulates the balance between pro-inflammatory and anti-inflammatory states
- TREML2 participates in cellular debris clearance
- Involved in phagocytosis of apoptotic cells and pathogens
- Complements TREM2-mediated phagocytosis in myeloid cells
- Acts as a co-stimulatory molecule for T-cell activation
- Modulates dendritic cell maturation and antigen presentation
- Regulates platelet activation and function
In the brain, TREML2 is expressed by microglia and modulates [13][14]:
- TREML2 contributes to amyloid-beta clearance
- Regulates microglial uptake of cellular debris
- Modifies the microglial inflammatory response to pathological stimuli
- TREML2 signaling influences cytokine production by microglia
- Can modulate the neurotoxic vs. protective microglial phenotype
- May be involved in the transition from acute to chronic neuroinflammation
TREML2 is genetically and functionally associated with AD risk [15][16][17]:
- TREML2 variants influence AD risk, though with smaller effect size than TREM2
- Certain TREML2 polymorphisms are associated with increased disease risk
- The genetic effect may be independent of or interact with TREM2 variants
- TREML2 modulates microglial activation and phagocytosis
- Influences amyloid clearance efficiency
- Regulates neuroinflammation in the AD brain
- TREML2 agonists may enhance beneficial microglial responses
- Targeting TREML2 could complement TREM2-based therapies
- May provide an alternative approach for AD immunotherapy
TREML2 may play a role in PD pathogenesis [18]:
- Altered TREML2 expression in PD brain tissue
- Potential involvement in alpha-synuclein clearance
- May modulate microglial responses to dopaminergic neuron injury
¶ Stroke and Ischemia
TREML2 has protective roles in ischemic injury [19]:
- Modulates inflammatory responses following stroke
- Promotes phagocytosis of necrotic debris
- May influence recovery through immune modulation
¶ Inflammatory and Autoimmune Diseases
TREML2 dysregulation contributes to various inflammatory conditions [20]:
- Altered expression in autoimmune diseases
- Modulates inflammatory responses in chronic inflammatory conditions
- Potential therapeutic target for immune-mediated diseases
Several therapeutic approaches are being developed [21][22]:
- Agonistic antibodies: Antibodies that activate TREM2/TREML2 signaling to enhance microglial function
- Small molecule agonists: Compounds that stimulate TREM2/TREML2 signaling pathways
- Protein replacement: Administration of soluble TREML2 or TREM2 ectodomains
Therapeutic modulation approaches include:
- Enhancing phagocytosis: Agonists to boost debris and amyloid clearance
- Shifting microglial phenotype: Modulators to promote neuroprotective microglial states
- Reducing neuroinflammation: Anti-inflammatory approaches via TREML2 modulation
TREML2 may serve as a biomarker:
- Soluble TREML2 (sTREML2) can be detected in cerebrospinal fluid
- Levels may correlate with disease stage or progression
- May help predict treatment response